Vaxart, Inc. (VXRT)
0.4344
0.00 (0.00%)
USD |
OTCM |
Oct 09, 16:00
Vaxart Net Income (Quarterly) : -13.49M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -13.49M |
| March 31, 2026 | 5.179M |
| December 31, 2025 | 55.04M |
| September 30, 2025 | -8.141M |
| June 30, 2025 | -14.99M |
| March 31, 2025 | -15.59M |
| December 31, 2024 | -11.98M |
| September 30, 2024 | -14.08M |
| June 30, 2024 | -16.47M |
| March 31, 2024 | -24.42M |
| December 31, 2023 | -17.38M |
| September 30, 2023 | -17.40M |
| June 30, 2023 | -22.55M |
| March 31, 2023 | -25.14M |
| December 31, 2022 | -23.92M |
| September 30, 2022 | -29.31M |
| June 30, 2022 | -29.43M |
| March 31, 2022 | -25.10M |
| December 31, 2021 | -20.76M |
| September 30, 2021 | -17.58M |
| June 30, 2021 | -16.12M |
| March 31, 2021 | -16.01M |
| December 31, 2020 | -13.86M |
| September 30, 2020 | -8.085M |
| June 30, 2020 | -8.977M |
| Date | Value |
|---|---|
| March 31, 2020 | -1.297M |
| December 31, 2019 | -6.409M |
| September 30, 2019 | -5.26M |
| June 30, 2019 | -5.637M |
| March 31, 2019 | -1.339M |
| December 31, 2018 | -4.902M |
| September 30, 2018 | -6.548M |
| June 30, 2018 | -8.871M |
| March 31, 2018 | 2.314M |
| June 30, 2017 | -5.90M |
| March 31, 2017 | -4.40M |
| December 31, 2016 | -9.10M |
| September 30, 2016 | -10.00M |
| June 30, 2016 | -7.00M |
| March 31, 2016 | -5.20M |
| December 31, 2015 | -6.50M |
| September 30, 2015 | -6.60M |
| June 30, 2015 | -19.90M |
| March 31, 2015 | 1.20M |
| December 31, 2014 | 6.50M |
| September 30, 2014 | -6.90M |
| June 30, 2014 | -10.20M |
| March 31, 2014 | 3.20M |
| December 31, 2013 | -0.10M |
| September 30, 2013 | -3.90M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Agenus, Inc. | -0.567M |
| Amgen, Inc. | 2.375B |
| Anika Therapeutics, Inc. | 3.309M |
| BioCryst Pharmaceuticals, Inc. | 78.40M |
| Imunon, Inc. | -2.814M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 27.18M |
| Total Expenses (Quarterly) | 40.68M |
| EPS Diluted (Quarterly) | -0.0557 |
| Enterprise Value | 54.05M |
| Gross Profit Margin (Quarterly) | 97.27% |
| Profit Margin (Quarterly) | -49.64% |
| Earnings Yield | 36.60% |
| Operating Earnings Yield | 38.24% |
| Normalized Earnings Yield | 36.60 |